<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00638638</url>
  </required_header>
  <id_info>
    <org_study_id>3233</org_study_id>
    <nct_id>NCT00638638</nct_id>
  </id_info>
  <brief_title>Myocardial Infarction With ST-Elevation</brief_title>
  <acronym>MISTRAL</acronym>
  <official_title>Myocardial Infarction With ST-elevation Treated by Primary Percutaneous Intervention Facilitated by Early Reopro Administration in Alsace.</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>University Hospital, Strasbourg, France</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Eli Lilly and Company</agency>
      <agency_class>Industry</agency_class>
    </collaborator>
  </sponsors>
  <source>University Hospital, Strasbourg, France</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      Mechanical recanalization of the culprit artery in acute myocardial infarction using stents
      provides in 2003, TIMI 3 flow restoration in more than 90% of patients. However, the
      prognosis of this condition remains poor, to a large degree because of microcirculatory
      dysfunction that is observed, in near than 20 to 40 % of patients, during or following
      primary percutaneous intervention. The lack of ST-segment elevation resolution after
      angioplasty with stenting is a marker of microcirculatory dysfunction and is associated with
      a poor prognosis. Routine administration with primary stenting of the platelet glycoprotein
      IIb/IIIa inhibitor Abciximab in acute myocardial infarction is still a matter of debate with
      conflicting results emerging from two major clinical studies ADMIRAL and CADILLAC. However,
      evidences are in favour of a benefit of this treatment especially when administrated early
      (in a pre-hospital manner) before percutaneous coronary intervention.Our primary purpose is
      to investigate the benefit of an early (i.e. pre-hospital) vs. a conventional (i.e.
      per-angiography) administration of Abciximab on ST-segment elevation regression at one hour
      after primary percutaneous angioplasty.
    </textblock>
  </brief_summary>
  <overall_status>Unknown status</overall_status>
  <last_known_status>Active, not recruiting</last_known_status>
  <start_date>January 2005</start_date>
  <completion_date type="Anticipated">January 2010</completion_date>
  <primary_completion_date type="Anticipated">August 2009</primary_completion_date>
  <phase>Phase 3</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Double (Participant, Investigator)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>ST segment regression 1 hour after angioplasty</measure>
    <time_frame>1 hour after angioplasty</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>Major cardiac events at 1 and 6 month</measure>
    <time_frame>1 and 6 month</time_frame>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">292</enrollment>
  <condition>Myocardial Infarction</condition>
  <arm_group>
    <arm_group_label>1</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Early Abciximab bolus during prehospital transportation in ambulance 0.25 mg/Kg iv with Heparin 40 UI/kg bolus.
Abciximab placebo bolus and Abciximab infusion 10 µg/Kg/min after coronary angiography and before angioplasty.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>2</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Abciximab placebo bolus during prehospital transportation in ambulance with Heparin 40 UI/kg bolus.
Abciximab 0.25 mg/Kg bolus after coronary angiography and before angioplasty followed by Abciximab infusion 10 µg/Kg/min.</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Abciximab</intervention_name>
    <description>Abciximab: 0.25 mg/Kg bolus
Abciximab placebo bolus
Abciximab infusion 10 µg/Kg/min</description>
    <arm_group_label>1</arm_group_label>
    <arm_group_label>2</arm_group_label>
    <other_name>1: Experimental</other_name>
    <other_name>2: Experimental</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Abciximab placebo</intervention_name>
    <description>Abciximab placebo Bolus
Abciximab: 0.25 mg/Kg bolus
Abciximab infusion 10 µg/Kg/min</description>
    <arm_group_label>1</arm_group_label>
    <arm_group_label>2</arm_group_label>
    <other_name>1: Experimental</other_name>
    <other_name>2: Experimental</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Patients over 18 years of age eligible for randomization in the MICU

          -  Infarct within 6 hours from symptoms onset

          -  Continuous typical chest pain symptoms symptoms for more than 20 min. and-ST segment
             elevation of more than 2 mm in more than two leads (peripheral or precordial)

          -  Signed informed consent form

        Exclusion Criteria:

          -  Ventricular conduction anomalies masking signs of ischemia (left or right bundle
             branch block without evidence of additional elevation), electrical left ventricular
             hypertrophy

          -  Known hypersensitivity to Abciximab or to any component of the product or to murine
             monoclonal antibodies.- Hemorrhagic diathesis, internal hemorrhage

          -  Hemorrhagic stroke within 2 years

          -  Ischemic stroke within the last 3 months- Intra-cranial neoplasm, intracranial
             malformation or arteria

          -  venous aneurysm

          -  Recent intracranial or intraspinal surgery or trauma (within two months)

          -  Recent within (2 months) major surgery- Known peptic ulcer or upper gastrointestinal
             bleeding within the previous 6 month

          -  Known coagulation anomaly

          -  Oral anti-coagulant or low molecular weight heparin treatment- Ongoing thrombolytic
             treatment
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Patrick OHLMANN, MD, PhD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Hôpitaux Universitaires de Strasbourg</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Service de Cardiologie - Hôpital de Hautepierre - 1, Avenue Molière</name>
      <address>
        <city>Strasbourg</city>
        <zip>67 098</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>France</country>
  </location_countries>
  <verification_date>September 2009</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>February 28, 2008</study_first_submitted>
  <study_first_submitted_qc>March 11, 2008</study_first_submitted_qc>
  <study_first_posted type="Estimate">March 19, 2008</study_first_posted>
  <last_update_submitted>September 16, 2009</last_update_submitted>
  <last_update_submitted_qc>September 16, 2009</last_update_submitted_qc>
  <last_update_posted type="Estimate">September 17, 2009</last_update_posted>
  <responsible_party>
    <name_title>Christine GEILLER, directeur Adjoint</name_title>
    <organization>University Hospital, Strasbourg, France</organization>
  </responsible_party>
  <keyword>Myocardial infarction</keyword>
  <keyword>Angioplasty</keyword>
  <keyword>Coronary stenting</keyword>
  <keyword>Abciximab</keyword>
  <keyword>Myocardial reperfusion</keyword>
  <keyword>Microcirculation</keyword>
  <keyword>EKG</keyword>
  <keyword>ST elevation myocardial infarction within 6 h of symptom onset</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Infarction</mesh_term>
    <mesh_term>Myocardial Infarction</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Abciximab</mesh_term>
    <mesh_term>Antibodies, Monoclonal</mesh_term>
    <mesh_term>Immunoglobulin Fab Fragments</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

